Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.

about

Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.

Item

http://www.wikidata.org/entity/Q50550101

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Combination therapy with losar ...... rld clinical setting in Japan.

@en

Combination therapy with losar ...... rld clinical setting in Japan.

@nl

type

Item

label

Combination therapy with losar ...... rld clinical setting in Japan.

@en

Combination therapy with losar ...... rld clinical setting in Japan.

@nl

prefLabel

Combination therapy with losar ...... rld clinical setting in Japan.

@en

Combination therapy with losar ...... rld clinical setting in Japan.

@nl

P1476

Combination therapy with losar ...... rld clinical setting in Japan.

@en

P2093

Hiromichi Suzuki

http://www.w3.org/2001/XMLSchema#string

Kenji Fujiwara

http://www.w3.org/2001/XMLSchema#string

Yukio Shimada

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004.

Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004.

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility

Optimizing blood pressure control through the use of fixed combinations

A practical approach to achieving recommended blood pressure goals in diabetic patients.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Angiotensin receptor blockers: new considerations in their mechanism of action.

Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?

Now or never: optimal antihypertensive therapy in the elderly.

Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

P304

237-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944712464285

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23129531

http://www.w3.org/2001/XMLSchema#string